Profile data is unavailable for this security.
About the company
Beijing Wantai Biopharmaceutical Co., Ltd. is a company mainly engaged in the research and development, production and sales of in-vitro diagnostics. The Company produces and sells in-vitro diagnostics, in-vitro diagnostic equipment and vaccines. The Company is also engaged in the sales of agent products. The in-vitro diagnostics include: enzyme-linked immunosorbent assay (ELISA) reagents, chemiluminescence reagents, biochemical reagents and quality control products. The in-vitro diagnostic instruments mainly include the automatic chemiluminescence immunoassay analyzer. The primary product of vaccine products is Hecolin used for hepatitis E. The agent products are in-vitro diagnostics and in-vitro diagnostic equipment from Bio-Rad Laboratories Inc in the U.S. and Diagast SAS in France.
- Revenue in CNY (TTM)3.38bn
- Net income in CNY128.47m
- Incorporated1991
- Employees3.84k
- LocationBeijing Wantai Biological Pharmacy Enterprise Co LtdNo.31 Science Park RoadChangping DistrictBEIJING 102206ChinaCHN
- Phone+86 1 059528820
- Fax+86 1 089705849
- Websitehttps://www.ystwt.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Tiantan Biological Products Corp | 5.11bn | 1.16bn | 48.28bn | 4.86k | 41.46 | 4.76 | -- | 9.45 | 0.7068 | 0.7068 | 3.10 | 6.15 | 0.3611 | 0.9104 | 171.46 | 1,051,960.00 | 11.18 | 11.71 | 16.00 | 16.50 | 52.26 | 49.39 | 30.97 | 27.71 | 3.41 | -- | 0.0094 | 16.67 | 21.57 | 12.06 | 25.99 | 16.85 | 29.67 | 38.97 |
| Shanghai Fosun Pharmaceutical (Group) | 40.69bn | 2.01bn | 57.18bn | 40.37k | 31.52 | 1.37 | -- | 1.41 | 0.7525 | 0.7525 | 15.24 | 17.36 | 0.368 | 2.90 | 5.28 | 1,007,829.00 | 2.32 | 4.31 | 3.83 | 7.01 | 46.73 | 50.71 | 6.31 | 10.65 | 0.79 | -- | 0.3818 | 31.92 | -5.81 | 10.69 | -36.04 | -2.50 | 10.95 | -3.34 |
| Beijing Tongrentang Co Ltd | 17.99bn | 1.72bn | 64.16bn | 16.78k | 37.27 | 4.72 | -- | 3.57 | 1.26 | 1.26 | 13.11 | 9.90 | 0.6079 | 1.23 | 10.82 | 1,072,010.00 | 8.84 | 8.20 | 16.50 | 16.17 | 45.32 | 46.59 | 14.55 | 13.33 | 2.28 | -- | 0.1632 | 30.93 | 16.19 | 4.68 | 16.92 | 8.03 | -12.01 | 13.97 |
| Sichuan Biokin Pharmaceutical Co Ltd | 5.90bn | 4.39bn | 75.99bn | 2.09k | 17.31 | 14.74 | -- | 12.88 | 10.95 | 10.95 | 14.71 | 12.86 | 1.37 | 1.85 | 41.29 | 2,828,652.00 | 102.16 | -- | 138.88 | -- | 95.70 | -- | 74.42 | -- | 3.75 | 828.87 | 0.1314 | -- | -20.11 | -- | -176.40 | -- | -- | -- |
| Beijing Wantai Biolog Pha Ent Co Ltd | 3.38bn | 128.47m | 83.61bn | 3.84k | 706.57 | 6.51 | -- | 24.76 | 0.0933 | 0.0933 | 2.68 | 10.12 | 0.2058 | 0.8371 | 0.8434 | 878,660.70 | 0.7531 | 24.08 | 0.9228 | 31.80 | 76.97 | 85.18 | 3.66 | 34.95 | 3.84 | -- | 0.0258 | 9.88 | -50.73 | 41.18 | -73.65 | 33.61 | 36.35 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fortune & Royal Asset Management Co., Ltd.as of 13 Jan 2023 | 15.52m | 1.23% |
| Generali China Asset Management Co. Ltd.as of 13 Jan 2023 | 10.35m | 0.82% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 7.72m | 0.61% |
| China Merchants Fund Management Co., Ltd.as of 30 Sep 2023 | 6.77m | 0.54% |
| Taikang Asset Management Co. Ltd.as of 13 Jan 2023 | 5.33m | 0.42% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2023 | 3.05m | 0.24% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2023 | 2.65m | 0.21% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2023 | 2.07m | 0.16% |
| GF Fund Management Co., Ltd.as of 30 Jun 2023 | 2.04m | 0.16% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2023 | 1.97m | 0.16% |
